BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 10960457)

  • 1. Antibodies against hepatitis C virus-like particles and viral clearance in acute and chronic hepatitis C.
    Baumert TF; Wellnitz S; Aono S; Satoi J; Herion D; Tilman Gerlach J; Pape GR; Lau JY; Hoofnagle JH; Blum HE; Liang TJ
    Hepatology; 2000 Sep; 32(3):610-7. PubMed ID: 10960457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C.
    Steinmann D; Barth H; Gissler B; Schürmann P; Adah MI; Gerlach JT; Pape GR; Depla E; Jacobs D; Maertens G; Patel AH; Inchauspé G; Liang TJ; Blum HE; Baumert TF
    J Virol; 2004 Sep; 78(17):9030-40. PubMed ID: 15308699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment.
    Mancini N; Carletti S; Perotti M; Romanò L; Craxì RD; Craxì A; Zanetti AR; Clementi M; Burioni R
    J Med Virol; 2006 Oct; 78(10):1304-11. PubMed ID: 16927283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential changes of hepatitis C virus antibody profiles during treatment of chronic hepatitis C of genotype 1b: pretreatment antibody response to E2/NS1 correlated sustained response.
    Chu CM; Sheen IS; Liaw YF
    Infection; 2004 Jun; 32(3):153-6. PubMed ID: 15188075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection.
    Lehmann M; Meyer MF; Monazahian M; Tillmann HL; Manns MP; Wedemeyer H
    J Med Virol; 2004 Jul; 73(3):387-91. PubMed ID: 15170633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of antibodies to hepatitis C virus glycoproteins 1 and 2 (anti-E1E2) with HCV disease.
    Hamed MR; Tarr AW; McClure CP; Ball JK; Hickling TP; Irving WL
    J Viral Hepat; 2008 May; 15(5):339-45. PubMed ID: 18221305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early antibody response against hypervariable region 1 is associated with acute self-limiting infections of hepatitis C virus.
    Zibert A; Meisel H; Kraas W; Schulz A; Jung G; Roggendorf M
    Hepatology; 1997 May; 25(5):1245-9. PubMed ID: 9141445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C.
    Ishii K; Rosa D; Watanabe Y; Katayama T; Harada H; Wyatt C; Kiyosawa K; Aizaki H; Matsuura Y; Houghton M; Abrignani S; Miyamura T
    Hepatology; 1998 Oct; 28(4):1117-20. PubMed ID: 9755251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus infection in dialysis and chronic liver patients: Viraemia dependent anti-E2-antibody response.
    Hanuka N; Sikuler E; Tovbin D; Neville L; Nussbaum O; Mostoslavsky M; Orgel M; Yaari A; Manor S; Dagan S; Hilzenrat N; Shemer-Avni Y
    J Med Virol; 2004 Aug; 73(4):529-35. PubMed ID: 15221896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up after successful interferon therapy of acute hepatitis C.
    Wiegand J; Jäckel E; Cornberg M; Hinrichsen H; Dietrich M; Kroeger J; Fritsch WP; Kubitschke A; Aslan N; Tillmann HL; Manns MP; Wedemeyer H
    Hepatology; 2004 Jul; 40(1):98-107. PubMed ID: 15239091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hepatitis C virus. Virological diagnosis].
    Lunel F; Pawlotsky JM
    Pathol Biol (Paris); 1995 Oct; 43(8):681-90. PubMed ID: 8745590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of specific antibodies to F protein in serum samples from Chinese hepatitis C patients treated with interferon plus ribavarin.
    Gao DY; Zhang XX; Hou G; Jin GD; Deng Q; Kong XF; Zhang DH; Ling Y; Yu DM; Gong QM; Zhan Q; Yao BL; Lu ZM
    J Clin Microbiol; 2008 Nov; 46(11):3746-51. PubMed ID: 18832124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies directed to envelope proteins of hepatitis C virus outside of hypervariable region 1.
    Lechner S; Rispeter K; Meisel H; Kraas W; Jung G; Roggendorf M; Zibert A
    Virology; 1998 Apr; 243(2):313-21. PubMed ID: 9568031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoglobulin G antibody avidity assay for serodiagnosis of hepatitis C virus infection.
    Kanno A; Kazuyama Y
    J Med Virol; 2002 Oct; 68(2):229-33. PubMed ID: 12210412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Murine antibodies against E2 and hypervariable region 1 cross-reactively capture hepatitis C virus.
    Esumi M; Ahmed M; Zhou YH; Takahashi H; Shikata T
    Virology; 1998 Nov; 251(1):158-64. PubMed ID: 9813211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-hepatitis C virus immunoglobulin M antibody in patients with chronic hepatitis type C.
    Kikuchi T; Onji M; Michitaka K; Ohta Y
    Hepatogastroenterology; 1992 Dec; 39(6):525-8. PubMed ID: 1336473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antigenic relevance of F protein in chronic hepatitis C virus infection.
    Komurian-Pradel F; Rajoharison A; Berland JL; Khouri V; Perret M; Van Roosmalen M; Pol S; Negro F; Paranhos-Baccalà G
    Hepatology; 2004 Oct; 40(4):900-9. PubMed ID: 15382175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical impact of genotype 1 TT virus infection in patients with chronic hepatitis C and response of TT virus to alpha-interferon.
    Nishizawa Y; Tanaka E; Orii K; Rokuhara A; Ichijo T; Yoshizawa K; Kiyosawa K
    J Gastroenterol Hepatol; 2000 Nov; 15(11):1292-7. PubMed ID: 11129224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to treatment with interferon-alfa in patients with chronic hepatitis C and high titers of -M2, -M4 and -M8 antimitochondrial antibodies.
    Garrido Palma G; Sánchez Cuenca JM; Olaso V; Pina R; Urquijo JJ; López Viedma B; Bustamante M; Berenguer M; Berenguer J
    Rev Esp Enferm Dig; 1999 Mar; 91(3):168-81. PubMed ID: 10231308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.